ERDERA at the Chan Zuckerberg Initiative workshop on systematically characterising rare diseases

ERDERA at the Chan Zuckerberg Initiative workshop on systematically characterising rare diseases

ERDERA coordination participated in the Chan Zuckerberg Initiative’s “Building a Roadmap to Systematically Characterize Rare Diseases” workshop, taking place March 24–26 at CZI Headquarters in Redwood City, California.

This convening brought together leaders from across academia, industry, and patient advocacy to co‑create a strategic framework for defining essential parameters of rare disease characterisation, refining assays and technologies, mapping shared biological mechanisms, and developing an actionable pilot programme.

ERDERA coordination was represented by Yanis Mimouni, ERDERA Assistant Coordinator, who contributed with the programmes perspective and expertise in fostering collaboration and driving progress towards scalable, cross‑organisation initiatives that advance and accelerate rare disease research.

The workshop was organised by the Chan Zuckerberg Initiative (CZI), a philanthropic organisation founded by Mark Zuckerberg and Priscilla Chan dedicated to addressing some of society’s most significant challenges, including disease eradication, educational improvement, and meeting the needs of local communities.

News & Updates

You might also be interested in

For rare diseases, where research often relies on limited animal models and small development teams, the regulatory acceptance of virtual control groups could help streamline early non‑clinical studies while maintaining a strong focus on patient safety.
Bringing clinicians, researchers, patient representatives and families together, the event examined how shorter diagnostic pathways depend not only on better tests, but on shared expertise, structured phenotyping and patient-centred support.
ERDERA and the European Genomic Data Infrastructure have signed a Memorandum of Understanding to strengthen collaboration on secure cross-border access to genomic, clinical and other health-related data, supporting rare disease research and the development of personalised medicine in Europe.
The two-day event will focus on translating research and policy initiatives into tangible benefits for Rare Disease patients through better prevention, diagnosis, and treatment.